Capital Fund Management (CFM)
FATE icon

Capital Fund Management (CFM)’s Fate Therapeutics FATE Stock Holding History

Capital Fund Management (CFM)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-304,105
Closed -$1.45M – 1984
2023
Q2 		$1.45M Buy
304,105
+232,494
+325% +$1.28M 0.01% 1296
2023
Q1 		$408K Sell
71,611
-37,935
-35% -$229K ﹤0.01% 1468
2022
Q4 		$1.11M Buy
+109,546
New +$2.06M 0.01% 1110
2020
Q4 		– Sell
-24,077
Closed -$962K – 1364
2020
Q3 		$962K Buy
24,077
+3,967
+20% +$139K 0.01% 886
2020
Q2 		$690K Buy
+20,110
New +$599K 0.01% 811
2020
Q1 		– Sell
-20,001
Closed -$391K – 1705
2019
Q4 		$391K Buy
+20,001
New +$318K ﹤0.01% 1496

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Fund Management (CFM)'s FATE Position: Q3 2023 in Review

Capital Fund Management (CFM) sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 304,105 shares — an estimated $1.45M sold.

Capital Fund Management (CFM) first reported a position in FATE in Q4 2019 and held it in 6 quarters. The position peaked at $1.45M in Q2 2023. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Capital Fund Management (CFM) reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 304,105 Fate Therapeutics shares in Q3 2023, an estimated $1.45M.
  • Capital Fund Management (CFM) first reported a position in Fate Therapeutics in Q4 2019 and held it in 6 quarters.
  • Capital Fund Management (CFM)'s Fate Therapeutics position peaked at $1.45M in Q2 2023.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2023, filed 14 Nov 2023.